An Open-label, Single Dose Pharmacokinetic Study Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Male Chinese Subjects With Hemophilia B

Trial Profile

An Open-label, Single Dose Pharmacokinetic Study Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Male Chinese Subjects With Hemophilia B

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Nonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 04 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 09 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 s reported by ClinicalTrials.gov.
    • 09 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top